{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:56:49Z","timestamp":1781614609660,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Regular laboratory testing is recommended for monitoring disease activity and adverse effects in people taking conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), yet the perspectives and experiences of patients have not been examined and may inform practice. As such, we aimed to determine the experiences and perceptions of laboratory monitoring in Australian adults using csDMARDs for rheumatoid arthritis (RA) or psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants in the Australian Rheumatology Association Database who had RA or PsA were sent an online questionnaire capturing their demographics, frequency of advised and actual blood tests, barriers, benefits and whether they felt they had been given an adequate rationale for testing or felt they needed more information. Data were reported using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The survey was distributed to 904 ARAD participants with RA and\/or PsA with 679 responses (75.1%). A total of 451 people (348 RA, 103 PsA) fulfilled inclusion criteria. Most respondents were female (72.3%) with a mean age of 63.2\u2009\u00b1\u200910.7 years. The mean disease duration was 25.0\u2009\u00b1\u200911.7 years, and most respondents (82.5%) were taking methotrexate. Respondents reported being asked to have blood tests most frequently every 12 weeks (30.1%), followed by 4 (14.6%), 26 weeks (14.4%) and 8 (13.0%) weeks. 70.5% reported that they had their blood tests either early or on time. Most respondents (87.4%) reported that they felt the rationale for blood tests had been properly explained to them, with 19.5% reporting they would like more information. Overall, few reported perceived risks and costs, while almost all reported perceived benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Australian adults with RA and PsA taking csDMARDs are typically adherent to the schedule of laboratory monitoring requested by their treating rheumatologists. For most respondents, they reported perceived benefits with few reporting risks or costs. These self-reported findings from a long-disease-duration cohort should be used to inform standardised national guidelines for laboratory monitoring of csDMARDs. Further research into the perceived gaps in patient understanding of the need for laboratory testing may further enhance adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-025-00573-0","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:53:46Z","timestamp":1761213226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient experiences and perspectives of DMARD monitoring in Australians with long-disease-duration rheumatoid arthritis and psoriatic arthritis"],"prefix":"10.1186","volume":"9","author":[{"given":"Morgan","family":"Witts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Stanhope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhasha","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Lassere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kubler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"6","key":"573_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological dmards: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"573_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.1780360307","volume":"36","author":"AM Walker","year":"1993","unstructured":"Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarc\u00f3n GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36(3):329\u201335.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"573_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/acr.22294","volume":"66","author":"G Schmajuk","year":"2014","unstructured":"Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res (Hoboken). 2014;66(8):1159\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"9614241","DOI":"10.1155\/2017\/9614241","volume":"2017","author":"WFC Rigby","year":"2017","unstructured":"Rigby WFC, Lampl K, Low JM, Furst DE. Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int J Rheumatol. 2017;2017:9614241.","journal-title":"Int J Rheumatol"},{"issue":"1","key":"573_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"573_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41927-022-00290-y","volume":"6","author":"JJ Tsakas","year":"2022","unstructured":"Tsakas JJ, Liew DFL, Adams CL, Hill CL, Proudman S, Whittle S, et al. Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees. BMC Rheumatol. 2022;6(1):59.","journal-title":"BMC Rheumatol"},{"issue":"2","key":"573_CR7","first-page":"405","volume":"63","author":"S Thompson","year":"2024","unstructured":"Thompson S, Druce KL, Ledingham J, Galloway JB, Kiely PD, Kirkham B, et al. Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology (Oxford). 2024;63(2):405\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"573_CR8","unstructured":"Australian Government Department of Health and Aged Care. Medicare costs Canberra: Australian Government. 2022. Available from: https:\/\/www.health.gov.au\/topics\/medicare\/about\/costs"},{"key":"573_CR9","unstructured":"Healthdirect Australia. Paying for diagnostic testing: Healthdirect Australia Ltd. 2025. Available from: https:\/\/www.healthdirect.gov.au\/paying-for-diagnostic-testing"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41927-020-00126-7","volume":"4","author":"HEL Masri","year":"2020","unstructured":"Masri HEL, Hollingworth SA, van Driel M, Benham H, McGuire TM. Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center. BMC Rheumatol. 2020;4:27.","journal-title":"BMC Rheumatol"},{"issue":"10","key":"573_CR11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/acr.22048","volume":"65","author":"JR Curtis","year":"2013","unstructured":"Curtis JR, Harrold YS, Zhang L, Greenberg J, Reed JD. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013;65(10):1707\u201312.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"573_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/acr.22531","volume":"67","author":"I Nota","year":"2015","unstructured":"Nota I, Drossaert CHC, Taal E, van de Laar MAFJ. Patients\u2019 considerations in the decision-making process of initiating disease\u2010modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2015;67(6):956\u201364.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"573_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/jme.2007.023705","volume":"34","author":"J Schildmann","year":"2008","unstructured":"Schildmann J, Grunke M, Kalden JR, Vollmann J. Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis. J Med Ethics. 2008;34(11):775\u20139.","journal-title":"J Med Ethics"},{"key":"573_CR14","unstructured":"Australian Rheumatology Association. Australian living guidelines for the management of adult rheumatoid arthritis New Farm: Australian Rheumatology Association. 2024. Available from: https:\/\/rheumatology.org.au\/For-Healthcare-Professionals\/Australian-Living-Guidelines\/Adult-Living-Guidelines"},{"issue":"10","key":"573_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/imj.15816","volume":"52","author":"SL Whittle","year":"2022","unstructured":"Whittle SL, Glennon V, Johnston RV, Avery JC, Bell JS, Brennan SE, et al. Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis. Intern Med J. 2022;52(10):1799\u2013805.","journal-title":"Intern Med J"},{"issue":"9","key":"573_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1445-5994.2007.01431.x","volume":"37","author":"R Buchbinder","year":"2007","unstructured":"Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, et al. Effect of treatment with biological agents for arthritis in australia: the Australian rheumatology association database. Intern Med J. 2007;37(9):591\u2013600.","journal-title":"Intern Med J"},{"issue":"4","key":"573_CR17","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.semarthrit.2010.10.001","volume":"40","author":"MP Williams","year":"2011","unstructured":"Williams MP, Buchbinder R, March L, Lassere M. The Australian rheumatology association database (ARAD). Semin Arthritis Rheum. 2011;40(4):e2\u20133.","journal-title":"Semin Arthritis Rheum"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"issue":"2","key":"573_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translation research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"key":"573_CR20","volume-title":"Census of population and housing: Socio-Economic indexes for areas (SEIFA) - Technical paper","author":"Australian Bureau of Statistics","year":"2021","unstructured":"Australian Bureau of Statistics. Census of population and housing: socio-economic indexes for areas (SEIFA) - Technical paper. Canberra: Australian Bureau of Statistics; 2021."},{"key":"573_CR21","first-page":"21","volume":"7","author":"NS Morris","year":"2006","unstructured":"Morris NS, MacLean CD, Chew LD, Littenberg B. The single item literacy screener: evaluation of a brief instrument to identify limited reading ability. BMC Prim Care. 2006;7:21.","journal-title":"BMC Prim Care"},{"issue":"3","key":"573_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1008815005736","volume":"8","author":"G Hawthorne","year":"1999","unstructured":"Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209\u201324.","journal-title":"Qual Life Res"},{"issue":"1","key":"573_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1\u201324.","journal-title":"Psychol Health"},{"key":"573_CR24","volume-title":"Stata statistical software: release 18. College station","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata statistical software: release 18. College station. TX: StataCorp LLC; 2023."},{"issue":"Suppl 1","key":"573_CR25","first-page":"711","volume":"83","author":"MA Ulijn","year":"2024","unstructured":"Ulijn MA, Kievit W, van der Goes MC, de Jong P, Jansen TL, Lems WF, et al. The frequency of long-term routine laboratory toxicity monitoring in rheumatoid arthritis patients using disease modifying anti-rheumatic drugs can be vastly reduced: a large long-term cohort study. Ann Rheum Dis. 2024;83(Suppl 1):711.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"573_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00296-018-4016-2","volume":"38","author":"S Georgopoulou","year":"2018","unstructured":"Georgopoulou S, Prothero L, D\u2019Cruz DP. Physician-patient communication in rheumatology: a systematic review. Rheumatol Int. 2018;38(5):763\u201375.","journal-title":"Rheumatol Int"},{"issue":"6","key":"573_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1756-185X.13833","volume":"23","author":"N Leonardo","year":"2020","unstructured":"Leonardo N, Lester S, Graham M, Barrett C, Whittle S, Rowett D, et al. Selection and perception of methotrexate treatment information in people with rheumatoid arthritis. Int J Rheum Dis. 2020;23(6):805\u201312.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"573_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40744-021-00297-w","volume":"8","author":"I Lim","year":"2021","unstructured":"Lim I, Richette P, Queiro-Silva R, Moser J, Cappelleri JC, Ng HY, Witcombe D. Patient perceptions of psoriatic arthritis management and communication with physicians in australia: results from a patient survey. Rheumatol Ther. 2021;8(2):761\u201374.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"573_CR29","first-page":"206","volume":"130","author":"D M\u00fcting","year":"2022","unstructured":"M\u00fcting D, Lantzsch T, Pechtner T, et al. Adherence to a risk-adapted screening strategy for prostate cancer: first results of the PROBASE trial. BJU Int. 2022;130(2):206\u201313.","journal-title":"BJU Int"},{"key":"573_CR30","doi-asserted-by":"crossref","first-page":"101783","DOI":"10.1016\/j.eclinm.2022.101783","volume":"56","author":"P Kaul","year":"2023","unstructured":"Kaul P, Chu LM, Dover D, Yeung RO, Eurich DT, Butalia S. Disparities in adherence to diabetes screening guidelines among males and females in a universal care setting: a population-based study of 1,380,697 adults. eClinicalMedicine. 2023;56:101783.","journal-title":"eClinicalMedicine"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00573-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:15:48Z","timestamp":1781612148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-025-00573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00573-0","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics was approved by Metro North HREC A (EC00172) (Reference: LNR\/2021\/QRBW\/73446). Informed consent was obtained from all participants. Study outline, data usage and storage information were stated in an opening statement prior to survey commencement. A statement followed outlining that completing the survey would imply consent. ARAD has ethics approval from Monash University and the Central Adelaide Local Health Network.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}